Precision Medicine Simplified
Introducing an innovative approach to make
management of complex disorders simple,
fast, effective, and affordable.
Going Beyond Genetics to Guide Clinical Decisions
Integrating genetic, environmental, clinical data and curated guidelines from the world’s top experts to guide earlier diagnoses and patient-specific care plans.
Currently, many complex diseases are detected too late in their progression based on symptoms that can be misleading. Ariel goes beyond genetics to provide valuable information to clarify risk and guide a personalized approach to the early detection of complex diseases. Our reports are tailored to each patient, integrating patient reported outcomes, environmental and medical history into the interpretation of the genetic data.
Curated Single Nucleotide Polymorphism (SNP) Genotyping
Ariel uses pre-defined SNPs with known effects so that the impact can immediately be integrated into complex disease models and the analysis process is not slowed by exploring the possible impact of rare genetic variants of unknown significance (VUS). This approach optimizes speed and efficiency of the system as a screening tools with the recognition that additional genetic testing may be required to discover rare or complex genetic variants that are not commonly part of established disease models.
Ariel’s SNaP-Shot panels can be ordered remotely for patients and testing can be done in the privacy of their home using a cheek swab test. Ariel’s tests can be ordered by a licensed provider and the direct pay model ensures complete transparency into pricing.
Unravel Complex Conditions
Our platform integrates a patient’s symptoms and genetics with complex medical information.
Secure Online Test Management
Order and review test results, add medical team and request patient consent using our portal.
Comprehensive Genetic Testing
Analyzes multiple risk factors that are disease causing rather than just assessing single gene risk factors.
In addition to traditional Mendelian variants, Ariel reports disease modifying and complex genetic variants.
Our reports are tailored to each patient, integrating patient reported outcomes, environmental and medical history into the interpretation of the genetic data.
Our platform provides you with clinical considerations according to guidelines and continuously updates you and your patients if variants are reclassified.
Our platform uses high quality array technology in a CLIA-certified laboratory.
A genotyping-array test of over 60 genetic variants related to the risk for pancreatitis, celiac disease, gallstones, and hypertriglyceridemia. Also includes a polygenic risk score (PRS) for type 2 diabetes mellitus.
ABCG8, APOA5, APOB, CASR, CFTR, CLDN2, CTRC, GGT1, HLA-DQA1, HLA-DQB1, LPL, PRSS1, PRSS1-PRSS2, SLC10A2, SLC26A9 and SPINK1.
Genetic testing for pancreatitis is recommended for individuals with pancreatitis that meet one or more of the following criteria:
- An unexplained episode of acute pancreatitis in childhood
- Recurrent acute or chronic pancreatitis without a known cause, particularly with early-onset
- A family history of pancreatitis of unknown cause
- A family history of pancreatitis with an established genetic cause
- Additional symptoms consistent with a genetic disorder that includes pancreatitis as a symptom, such as cystic fibrosis or a CFTR-related disorder
- Additionally, individuals that meet any of the following criteria may also benefit from genetic testing:
- One or more attacks (or suspected attacks) of acute pancreatitis
- Abdominal pain after eating, chronic diarrhea, abnormal findings on a CT or MRI scan, or an abnormal laboratory test related to the pancreas
- Zhou D, Bai R, Wang L. The Cystic Fibrosis Transmembrane Conductance Regulator 470 Met Allele Is Associated with an Increased Risk of Chronic Pancreatitis in Both Asian and Caucasian Populations: A Meta-Analysis. Genet Test Mol Biomarkers. 2020 Jan;24(1):24-32. doi: 10.1089/gtmb.2019.0199. PMID: 31940241.
- Farrell, Philip M., et al. “Introduction to ‘Cystic Fibrosis Foundation Consensus Guidelines for Diagnosis of Cystic Fibrosis.’” The Journal of Pediatrics, vol. 181, 2017, doi:10.1016/j.jpeds.2016.09.062.
- Whitcomb DC, Yadav D, Adam S, Hawes RH, Brand RE, Anderson MA, Money ME, Banks PA, Bishop MD, Baillie J, Sherman S, DiSario J, Burton FR, Gardner TB, Amann ST, Gelrud A, Lo SK, DeMeo MT, Steinberg WM, Kochman ML, Etemad B, Forsmark CE, Elinoff B, Greer JB, O’Connell M, Lamb J, Barmada MM; North American Pancreatic Study Group. Multicenter approach to recurrent acute and chronic pancreatitis in the United States: the North American Pancreatitis Study 2 (NAPS2). Pancreatology. 2008;8(4-5):520-31. doi: 10.1159/000152001. Epub 2008 Sep 3. PMID: 18765957; PMCID: PMC2790781.
- Romagnuolo J, Talluri J, Kennard E, Sandhu BS, Sherman S, Cote GA, Al-Kaade S, Gardner TB, Gelrud A, Lewis MD, Forsmark CE, Guda NM, Conwell DL, Banks PA, Muniraj T, Wisniewski SR, Tian Y, Wilcox CM, Anderson MA, Brand RE, Slivka A, Whitcomb DC, Yadav D. Clinical Profile, Etiology, and Treatment of Chronic Pancreatitis in North American Women: Analysis of a Large Multicenter Cohort. Pancreas. 2016 Aug;45(7):934-40. doi: 10.1097/MPA.0000000000000616. PMID: 26967451; PMCID: PMC4940220.
- Miller AC, Comellas AP, Hornick DB, Stoltz DA, Cavanaugh JE, Gerke AK, Welsh MJ, Zabner J, Polgreen PM. Cystic fibrosis carriers are at increased risk for a wide range of cystic fibrosis-related conditions. Proc Natl Acad Sci U S A. 2020 Jan 21;117(3):1621-1627. doi: 10.1073/pnas.1914912117. Epub 2019 Dec 27. PMID: 31882447; PMCID: PMC6983448.
- LaRusch, Jessica et al. “The Common Chymotrypsinogen C (CTRC) Variant G60G (C.180T) Increases Risk of Chronic Pancreatitis But Not Recurrent Acute Pancreatitis in a North American Population.” Clinical and translational gastroenterology vol. 6,1 e68. 8 Jan. 2015, doi:10.1038/ctg.2014.13.
- Tremblay, Karine et al. “Association of CTRC and SPINK1 gene variants with recurrent hospitalizations for pancreatitis or acute abdominal pain in lipoprotein lipase deficiency.” Frontiers in genetics vol. 5 90. 22 Apr. 2014, doi:10.3389/fgene.2014.00090.
- Muddana V, Lamb J, Greer JB, Elinoff B, Hawes RH, Cotton PB, Anderson MA, Brand RE, Slivka A, Whitcomb DC. Association between calcium sensing receptor gene polymorphisms and chronic pancreatitis in a US population: role of serine protease inhibitor Kazal 1type and alcohol. World J Gastroenterol. 2008 Jul 28;14(28):4486-91. doi: 10.3748/wjg.14.4486. PMID: 18680227; PMCID: PMC2731274.
- Kimura S, Okabayashi Y, Inushima K, Yutsudo Y, Kasuga M. Polymorphism of cystic fibrosis gene in Japanese patients with chronic pancreatitis. Dig Dis Sci. 2000 Oct;45(10):2007-12. doi: 10.1023/a:1005500210281. PMID: 11117575.
- Radosavljevic I, Stojanovic B, Spasic M, Jankovic S, Djordjevic N. CFTR IVS8 Poly-T Variation Affects Severity of Acute Pancreatitis in Women. J Gastrointest Surg. 2019 May;23(5):975-981. doi: 10.1007/s11605-018-3913-8. Epub 2018 Aug 21. PMID: 30132293.
- Steiner B, Rosendahl J, Witt H, Teich N, Keim V, Schulz HU, Pfützer R, Löhr M, Gress TM, Nickel R, Landt O, Koudova M, Macek M Jr, Farre A, Casals T, Desax MC, Gallati S, Gomez-Lira M, Audrezet MP, Férec C, des Georges M, Claustres M, Truninger K. Common CFTR haplotypes and susceptibility to chronic pancreatitis and congenital bilateral absence of the vas deferens. Hum Mutat. 2011 Aug;32(8):912-20. doi: 10.1002/humu.21511. Epub 2011 Jun 7. Erratum in: Hum Mutat. 2012 Feb;33(2):456. Lühr, Matthias [corrected to Löhr, Matthias]. PMID: 21520337.
- Yu-Ting Chang, Ming-Chu Chang, Ta-Chen Su, Po-Chin Liang, Yi-Ning Su, Chun-Hung Kuo, Shu-Chen Wei, Jau-Min Wong, Association of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation/Variant/Haplotype and Tumor Necrosis Factor (TNF) Promoter Polymorphism in Hyperlipidemic Pancreatitis, Clinical Chemistry, Volume 54, Issue 1, 1 January 2008, Pages 131–138, https://doi.org/10.1373/clinchem.2007.093492.
- Du, Qiang et al. “The CFTR M470V, intron 8 poly-T, and 8 TG-repeats detection in Chinese males with congenital bilateral absence of the vas deferens.” BioMed research international vol. 2014 (2014): 689185. doi:10.1155/2014/689185
- Cuppens H, Lin W, Jaspers M, Costes B, Teng H, Vankeerberghen A, Jorissen M, Droogmans G, Reynaert I, Goossens M, Nilius B, Cassiman JJ. Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. J Clin Invest. 1998 Jan 15;101(2):487-96. doi: 10.1172/JCI639. PMID: 9435322; PMCID: PMC508589.
- Phillips AE, Ooka K, Pothoulakis I, Paragomi P, Komara N, Lahooti A, Harb D, Mays M, Koutroumpakis F, Stello K, Greer PJ, Whitcomb DC, Papachristou GI. Assessment of Weight Loss and Gastrointestinal Symptoms Suggestive of Exocrine Pancreatic Dysfunction After Acute Pancreatitis. Clin Transl Gastroenterol. 2020 Dec 15;11(12):e00283. doi: 10.14309/ctg.0000000000000283. PMID: 33464001; PMCID: PMC7743841.
$299 for Pancreatitis SNaP-Shot
Pharmacogenomics SNaP-Shot (PGx) is an affordable clinical pharmacogenomics test and interpretation service that helps identify how patients are likely to respond to a medication or a specific medication dose. By analyzing genetic variants from 27 genes, Pharmacogenomics SNaP-Shot provides genetic insights to match appropriate medication and dosage to patients. It can also help avoid adverse drug events that are associated with specific genetic variants. Pharmacogenomics SNaP-Shot covers more than 125 medications used to treat a wide range of medical conditions.
- Provide guidance before a new medication is prescribed.
- Patient history of poor drug response.
- Patient history of adverse drug reactions.
- Patient prescribed multiple medications.
- Family history of poor response to medications.
- Pharmacogenomics SNaP-Shot (PGx) testing is not available for all drugs.
- Pharmacogenomics SNaP-Shot (PGx) does not test for all known or future Pharmacogenomics SNaP-Shot (PGx) associations.
- Current medications should not be changed based on PGx results without consulting with the prescriber.
- FDA (2020). Table of Pharmacogenetic Associations.
- Johnson JA, et al. (2017). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Pharmacogenomics-Guided Wafarin Dosing: 2017 Update. Clinical Pharmacology and Therapeutics.
- Moriyama B, et al. (2017). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy. Clinical Pharmacology and Therapeutics.
- Scott SA, et al. (2013). Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update. Clinical Pharmacology and Therapeutics.
How It Works
Ariel's Testing Process is Simple!
After the order has been placed, your patient will receive an email invitation to complete registration for testing.
A DNA collection kit will be shipped to your patient’s home. They will collect their DNA sample and send it back to us for analysis.
You will receive an email notification letting you know that the genetic report is ready to review. You will be able to review the report online.
Order A SNaP-Shot Genetic Panel To Start Personalizing Your Patient's Care Plan Today!
Frequently Asked Questions
An emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person.
Identifying the underlying biological causes of your patient’s pancreatitis symptoms can help direct therapy and guide medical management specific to the patient’s disease process. For example, genetic conditions such as hereditary pancreatitis and cystic fibrosis can both increase the risk of pancreatitis, but involve different treatments and clinical considerations. Early detection of the cause or causes of the disease process may prevent extensive diagnostic evaluations, delayed diagnosis and more severe end-stage disease.
A person’s genetic variants can impact how they will respond to medications (pharmacogenomics, PGx). PGx data can help you identify patients who are more likely to respond to a medication or a specific medication dose. It can also help patients avoid adverse drug events that are associated with specific genetic variants.
SNaP-Shot genetic analysis goes beyond genetics to incorporate genetic testing, patient medical and family history, patient biomarkers, and up-to-date management considerations to provide a comprehensive and actionable precision medicine report.
Pancreatitis SNaP-Shot tests for predisposition to both Mendelian (monogenic) and complex (multifactorial) forms of disease. A minority of pancreatitis patients have a monogenic cause of disease. Therefore, testing for predisposing risk variants in addition to monogenic disease variants assures a complete picture of known genetic predisposition.
is an affordable clinical pharmacogenomics (PGx) test and interpretation service that helps identify how patients are likely to respond to a medication or a specific medication dose. By analyzing genetic variants from 27 genes, Ariel SNaP-Shot provides genetic insights to match appropriate medication and dosage to patients. It can also help avoid adverse drug events that are associated with specific genetic variants. Pharmacogenomics SNaP-Shot covers more than 125 medications used to treat a wide range of medical conditions.
- Pancreatitis SNaP-Shot is a clinician-ordered test. To begin, create an account through the easy-to-use and secure Ariel online provider portal to place the order.
- Once the order is placed, your patient will receive an email from Ariel inviting them to register online, sign consent forms, pay for testing, access help resources, and complete their health profile.
- A cheek swab kit will be mailed to your patient’s home. The patient will be provided with instructions to swab the inside of their cheek and return their DNA sample by mail.
- Pancreatitis SNaP-Shot $299.
- Pharmacogenomics SNaP-Shot $249.
- Both tests $399.
No, Ariel does not offer genetic counseling services.
Ariel offers educational materials on pancreatitis, genetic testing, complex diseases and other pertinent topics for clinicians and patients inside the portal. Patient counseling materials for use during informed consent discussions and test ordering are available.
Please tell your patient to expect an email from Ariel. Once you place an order in the secure portal, Ariel will send your patient a ‘Welcome’ email with a link to Ariel’s secure patient portal to register. The patient can follow the instructions in their email to register in Ariel’s online portal, provide payment information, complete the informed consents, and their registration profile. Once the registration forms are complete, Ariel ships a DNA testing kit to the patient’s preferred shipping address. The Ariel test kit includes all materials and resources necessary to support the patient in collecting and returning their sample for testing.
A new collection kit will be sent to the patient.
The turnaround time for test results is 4-6 weeks.
Please contact firstname.lastname@example.org or 844-692-7435 to request a sample report.
Still Have Questions?
If you still have questions, we would love to answer them. Request a quick call with our team and we’ll be in touch.
1. de Pretis N, Amodio A, Frulloni L. Hypertriglyceridemic pancreatitis: Epidemiology, pathophysiology and clinical management. United European Gastroenterol J. 2018 Jun;6(5):649-655.
2. Allison Rosenzweig, PhD. “Which Patients Should Undergo Genetic Testing?” Pancreatic Cancer Action Network, PanCAN, 31 Jan. 2020, www.pancan.org/news/new-study-encourages-genetic-testing-for-all-pancreatic-cancer-patients-regardless-of-family-history/.